《復牌公告》藥明生物(02269.HK)力爭本年收入實現10%增長 明年下半年逐步回暖
藥明生物(02269.HK)就今日業務最新消息會議聲明,強調集團的業務營運及財務狀況維持強勁勢頭,且業務營運及財務狀況並未發生重大不利變動。儘管生物技術融資放緩導致生物技術行業呈個位數年增長率,且COVID-19相關項目的收入下降及幾個重磅藥的生產延期,導致2023年標收入增長低於預期,但公司仍對未來前景保持樂觀,旨在於2023年實現整體收入約10%增長,並繼續投資提升能力及產能,以在2024年及2025年保持強勁的毛利及增長率。展望未來,相信毛利率及增長率於2023年最具挑戰,並預期2024年下半年逐步回暖。
公司股份已申請周二(5日)恢復買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.